ESSA Pharma (EPIX) AI Stock Analysis

• Market Cap: $10.96M
• Dividend Yield: 731.3%
• Average Volume (3M): 11.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: N/A
• EPS Growth: 9.03%
• Country: US
• Employees: 35
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 47,308,395
• 10 Day Avg. Volume: 33,739,151
• 30 Day Avg. Volume: 11,458,052
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -3.12
• Enterprise Value/Revenue: -251.63
• Enterprise Value/Gross Profit: -8.45K
• Enterprise Value/Ebitda: 1.31
• 1Y Price Target: $2.25
• Price Target Upside: 878.26% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ―

ESSA Pharma's overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.

Positive Factors

Financial Flexibility

EPIX's last reported cash balance of $126.8M offers flexibility to evaluate opportunities.

Strategic Opportunities

The company will move to a strategic process in which it will explore options that maximize shareholder value.

Negative Factors

Clinical Trials

EPIX announced the discontinuation of masofaniten's randomized Phase II trial in combination with enzalutamide in anti-androgen naive mCPRC following an interim analysis that suggested the trial was unlikely to meet the primary endpoint.

Drug Development

EPIX announced that it will discontinue all masofaniten development following a pre-specified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study in mCRPC patients naïve to second-generation antiandrogens.

ESSA Pharma Business Overview & Revenue Model

Company Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

How the Company Makes Money

ESSA Pharma generates revenue primarily through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships often involve milestone payments and royalties based on the successful development and commercialization of its product candidates. Additionally, the company may secure funding through research grants and equity financing to support its clinical trials and drug development processes. While ESSA Pharma is in the clinical-stage and does not yet have commercialized products, its potential for revenue generation lies in the successful progression and eventual approval of its drug candidates, leading to licensing deals or acquisition opportunities.

ESSA Pharma Financial Statement Overview

Summary

ESSA Pharma's financial performance is weak due to zero revenue generation and consistent losses indicated by negative net income and EBIT. The strong cash position offers some stability, but ongoing negative cash flows and reliance on equity financing create sustainability concerns.

Income Statement

ESSA Pharma has reported zero revenue in the TTM (Trailing-Twelve-Months) and previous years, indicating a lack of top-line growth. The company is experiencing significant negative net income and EBIT, reflecting ongoing operational challenges and substantial losses.

Balance Sheet

The balance sheet shows a strong cash position with net cash, reflecting conservative financial management. However, the firm is heavily reliant on equity financing, as evidenced by a very low debt-to-equity ratio. This suggests limited financial leverage but also a lack of traditional debt funding, which might constrain growth opportunities.

Cash Flow

Operating cash flows are consistently negative, indicating cash burn, which is typical for early-stage biotech firms. Despite this, investing cash flows have been positive lately, possibly due to asset divestments or financing inflows. Free cash flow remains negative, highlighting ongoing cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	135.75K	0.00	0.00	0.00	0.00	0.00
Gross Profit	4.04K	-90.68K	-118.49K	-121.79K	-109.46K	-110.32K
EBITDA	-26.17M	-28.45M	-26.46M	-35.08M	-36.71M	-23.01M
Net Income	-25.27M	-28.54M	-26.58M	-35.10M	-36.81M	-23.45M
Balance Sheet
Total Assets	110.50M	128.11M	149.12M	169.50M	198.17M	80.58M
Cash, Cash Equivalents and Short-Term Investments	109.62M	126.76M	148.08M	57.08M	194.93M	56.32M
Total Debt	0.00	329.26K	80.33K	209.83K	330.97K	59.09K
Total Liabilities	1.60M	3.51M	3.50M	2.39M	4.16M	1.33M
Stockholders Equity	108.90M	124.61M	145.63M	167.12M	194.01M	79.24M
Cash Flow
Free Cash Flow	-20.88M	-22.72M	-19.78M	-28.70M	-25.42M	-16.98M
Operating Cash Flow	-20.88M	-22.72M	-19.78M	-28.70M	-25.42M	-16.98M
Investing Cash Flow	20.79M	91.79M	-3.53M	-52.35M	-35.01M	-21.74M
Financing Cash Flow	59.67K	925.51K	-68.16K	252.74K	141.99M	41.78M

ESSA Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.23
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EPIX, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.24, and above the 200-day MA of 0.22, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.66 is Neutral, neither overbought nor oversold. The STOCH value of 0.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EPIX.

ESSA Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.92B	-0.43	-41.69%	2.21%	22.29%	-1.85%
TCRX	48 Neutral	$107.25M	―	-63.33%	―	-42.94%	―
ADAG	47 Neutral	$100.86M	―	-63.24%	―	-87.65%	11.76%
EPIX	46 Neutral	$10.96M	―	-21.25%	731.30%	―	9.03%
IMAB	45 Neutral	$344.49M	―	-22.37%	―	-100.00%	72.53%
ADVM	41 Neutral	$66.52M	―	-222.28%	―	―	1.80%
UNCY	28 Underperform	$76.30M	―	-3987.11%	―	―	68.02%

ESSA Pharma Corporate Events

ESSA Pharma Introduces New Executive Severance Plan

ESSA Pharma Inc. has introduced a new Severance Plan, replacing previous cash severance benefits for certain executive officers. This plan offers cash severance ranging from 1 to 1.5 times an officer’s base salary, with additional compensation for the CEO, tied to events like a Change in Control. The plan aims to retain key executives by providing economic security in case of qualifying terminations, ensuring stability and encouraging dedication to the company’s growth.